GlassScriptPhysician profile
Jose C Costa
NPI 1043491830
$2,832.97
in general payments reported to CMS, 2019-2025
21 companies · $592 in 2025
The $592 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $174 · 2020: $81.94 · 2021: $398 · 2022: $562 · 2023: $509 · 2024: $516 · 2025: $592.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,598 · Education: $19.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,597.56 |
| Education | $19.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $795.14 | 2019-2025 | Linzess, Viberzi, Rinvoq |
| Ironwood Pharmaceuticals, INC | $693.53 | 2019-2024 | Linzess |
| Boston Scientific Corporation | $243.04 | 2023-2025 | Watchman Flx, Watchman |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $193.08 | 2019-2024 | Plenvu, Xifaxan |
| Pfizer INC. | $168.47 | 2019-2025 | |
| Redhill Biopharma INC. | $117.52 | 2021-2025 | Talicia, Aemcolo |
| Braintree Laboratories, INC. | $107.34 | 2019-2025 | Sutab, Suflave |
| Janssen Biotech, INC. | $78.13 | 2022-2025 | Tremfya |
| Phathom Pharmaceuticals, INC. | $71.21 | 2025 | Voquezna |
| Celgene Corporation | $67.78 | 2021-2022 | |
| Intercept Pharmaceuticals, INC. | $49.83 | 2025 | |
| Lilly USA, LLC | $38.74 | 2024 | Omvoh |
| Celltrion USA INC. | $33.70 | 2024-2025 | Vegzelma |
| Ferring Pharmaceuticals INC. | $32.29 | 2022-2023 | Rebyota |
| Ardelyx, INC. | $31.09 | 2022-2025 | Ibsrela |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $25.80 | 2019-2020 | |
| Alfasigma USA, INC. | $24.68 | 2022 | |
| Aimmune Therapeutics, INC. | $18.55 | 2025 | Zenpep |
| Daiichi Sankyo INC. | $16.80 | 2023 | Injectafer |
| Otsuka America Pharmaceutical, INC. | $13.90 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Costa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.